A survey among breast cancer survivors: Treatment of the climacteric after breast cancer

Climacteric

Volumn 11, Issue 4, 2008, Pages 322-328

  Antoine, C ^a,b   Vandromme, J ^a   Fastrez, M ^a   Carly, B ^a   Liebens, F ^a   Rozenberg, S ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Breast cancer survivors; Climacteric treatment; Hormone replacement therapy; Menopause; Survey; Vasomotor symptoms

Indexed keywords

ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; ESTROGEN; PHYTOESTROGEN; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVOR; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HOT FLUSH; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL DYSFUNCTION; TREATMENT CONTRAINDICATION; VAGINAL DRYNESS; VASOMOTOR DISORDER;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; AROMATASE INHIBITORS; BELGIUM; BODY IMAGE; BREAST NEOPLASMS; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; LIBIDO; MIDDLE AGED; PHYTOTHERAPY; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SURVIVORS;

EID: 47749120262     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802244422     Document Type: Article

References (42)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. Lyon: IARC Press, 2001
2. American Cancer Society (ACS). Cancer Statistics Presentation, 2004
3. Berry DA, Cronin KA, Plevritis SK, et al. for the Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92
4. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. Clin Oncol 1999;17:2365-70
5. Lower EE, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 1999;8:949-54
6. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;23:501-9
7. Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA 1994;272:540-5
8. Brzezinski A. Management of menopause in women with breast cancer. Isr J Med Sci 1995;31:163-8
9. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53
10. Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-5
11. Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-82
12. Antoine C, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 2007;22:616-22
13. Franke HR, Brood-van Zanten MM, Burger CW, van der Mooren MJ, Kenemans P. Breast cancer and climacteric complaints: weighing up risks of hormone therapy against quality of life. Eur J Obstet Gynecol Reprod Biol 2007;134:143-6
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
15. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005;11:545-60
16. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82
17. Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol 2005;6:687-95
18. Col NF, Kim JA, Chlebowski RT. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005;7:R535-40
19. Batur P, Blixen CE, Moore HCF, Thacker HL, Xu M. Menopausal hormone therapy (HT) in patients with breast cancer. Maturitas 2006;53:123-32
20. von Schoultz B, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005;97:533-5
21. Trinh XB, Van Hal G, Weyler J, Tjalma WA. The thoughts of physicians regarding the need to start hormone replacement therapy in breast cancer survivors. Eur J Obstet Gynecol Reprod Biol 2006;124:207-11
22. Trinh XB, Peeters F, Tjalma WA. The thoughts of breast cancer survivors regarding the need for starting hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 2006;124:250-3
23. Hoda D, Perez DG, Loprinzi CL. Hot flashes in breast cancer survivors. Breast J 2003;9:431-8
24. Gainford MC, Simmons C, Nguyen H, Verma S, Clemons M. A practical guide to the management of menopausal symptoms in breast cancer patients. Support Care Cancer 2005;13:573-8
25. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-71
26. Deniz G, Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Treatment of premature menopause in breast cancer patients. Acta Chir Belg;2007;107:263-6
27. Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45-54
28. Navo MA, Phan J, Vaughan C, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 2004;22:671-7
29. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004;15:753-60
30. Cella D, Fallowfield L, Barker P, et al. on behalf of the ATAC Trialistsa9 Group. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-84
31. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16: 501-14
32. Paskett ED, Herndon JE 2nd, Day JM, et al. for the Cancer and Leukemia Group B. Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008 Mar 3 [Epub ahead of print]
33. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83
34. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64
35. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-6
36. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9
37. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007;14(Suppl 1):S20-41
38. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222-31
39. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45:29-38
40. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63
41. Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006;9:49-58
42. Greendale GA, Gold EB. Lifestyle factors: are they related to vasomotor symptoms and do they modify the effectiveness or side effects of hormone therapy? Am J Med 2005;118(Suppl 12B):148-54